Horizon Pharma plc Announces Presentation of ACTIMMUNE(R) Phase 2 Data in Friedreich's Ataxia. DUBLIN, IRELAND -- (Marketwired) -- 10/09/14
Positive Clinical Efficacy Signal Seen in Study of Twelve Patients; Company Planning Phase 3 Program
An abstract of the data has been published in a supplement to the Annals of Neurology and is being presented as a poster during the 139th Annual Meeting of the American Neurological Association in Baltimore, MD on Monday, October 13.
Friday, October 10, 2014
Subscribe to:
Posts (Atom)
